- Featured Product
- KD/KO Validated
MUC1/CA15-3 N-terminal Polyclonal antibody
MUC1/CA15-3 N-terminal Polyclonal Antibody for ELISA
Cat no : 19976-1-AP
|Sample-dependent, check data in validation data gallery|
19976-1-AP targets MUC1/CA15-3 N-terminal in WB, IHC, IF, CoIP, ELISA applications and shows reactivity with human samples.
|Cited Reactivity||human, mouse, canine|
|Host / Isotype||Rabbit / IgG|
|Full Name||mucin 1, cell surface associated|
|Calculated molecular weight||122 kDa|
|Observed molecular weight||122 kDa|
|GenBank accession number||J05582|
|Gene ID (NCBI)||4582|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
MUC1 is a type I transmembrane glycoprotein expressed by various epithelial cells of female reproductive tract, lung, breast, kidney, stomach, and pancreas. MUC1 is transcribed as a large precursor gene product, and upon translation, is cleaved in the endoplasmic reticulum, yielding two subunits: the large extracellular N-terminal subunit (MUC1-N, about 120-200 kDa) and the small cytoplasmic C-terminal subunit (MUC1-C, about 23-30 kDa). Among the known mucins, MUC1 is best studied and plays crucial roles in regulating many cellular properties, including cell proliferation, apoptosis, adhesion, and invasion. MUC1 is overexpressed in a wide range of human epithelial malignancies. This antibody was raised against the N-terminal region of human MUC1, thus it recognizes the 120 kDa extracellular MUC1.
ACS Appl Mater Interfaces
Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment.
Clin Cancer Res
Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models.
Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
Int J Nanomedicine
Integration of Dual Targeting and Dual Therapeutic Modules Endows Self-Assembled Nanoparticles with Anti-Tumor Growth and Metastasis Functions.
LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.
YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma.